HutchMED (China) LIMITED (HMDCF) Return on equity 2016–2025
HutchMED (China) LIMITED (HMDCF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
36.9%FY2025 · since FY2016: 6.3% → 36.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 36.9% | +31.9 pp |
| FY2024 | 5.0% | -8.8 pp |
| FY2023 | 13.8% | +72.9 pp |
| FY2022 | -59.1% | -39.4 pp |
| FY2021 | -19.7% | +6.2 pp |
| FY2020 | -26.0% | +10.8 pp |
| FY2019 | -36.8% | -17.6 pp |
| FY2018 | -19.2% | -13.4 pp |
| FY2017 | -5.8% | -12.1 pp |
| FY2016 | 6.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice